📰 Immunic News
Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
May 1, 2024
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
April 28, 2024
StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]
February 22, 2024
Biotech Stock News Bite - Immunic, Inc. (Nasdaq: IMUX) Year End 2023 Financial Results and Provides Corporate Update
February 16, 2024
Immunic (NASDAQ:IMUX – Get Free Report) will be announcing its earnings results before the market opens on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($0.51) EPS for […]
February 7, 2024
Immunic, Inc. (NASDAQ:IMUX – Free Report) – Analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Immunic in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.66) per share for the year. The consensus estimate […]
November 21, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
October 26, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
October 15, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
October 14, 2023
Immunic (NASDAQ:IMUX – Free Report) had its price target lifted by Wedbush from $5.00 to $7.00 in a research note published on Tuesday, MarketBeat Ratings reports. The firm currently has an outperform rating on the stock. Separately, StockNews.com initiated coverage on Immunic in a research note on Thursday, October 5th. They issued a sell rating […]
October 4, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...